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Citrullination and carbamylation in
the pathophysiology of rheumatoid
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Ger J. M. Pruijn *
Department of Biomolecular Chemistry, Radboud Institute for Molecular Life Sciences, Institute for Molecules and Materials,
Radboud University, Nijmegen, Netherlands
The discovery that citrullination was crucial for the recognition of antigens by the most
disease-specific class of autoantibodies in rheumatoid arthritis (RA) had a huge impact on
studies aimed at understanding autoimmunity in this disease. In addition to the detailed
characterization of anti-citrullinated protein antibodies, various studies have addressed
the identity of citrullinated antigens. These investigations were facilitated by new methods
to characterize these proteins, the analysis of protein citrullination by peptidylarginine
deiminases, the generation of a catalog of citrullinated proteins present in the inflamed
joints of patients and the finding that the formation of extracellular traps is dependent on
the activity of peptidylarginine deiminase activity. Recently, it was found that in addition
to citrullination also carbamylation, which results in chemically highly related modified
proteins, yields antigens that are targeted by rheumatoid arthritis patient sera. Here, all
of these aspects will be discussed, culminating in current ideas about the involvement
of citrullination and carbamylation in pathophysiological processes in autoimmunity,
especially RA.
Keywords: carbamylation, citrullination, extracellular traps, NETosis, peptidylarginine deiminase, peptidylcitrulline,
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Introduction
Two forms of post-translational modification (PTM), citrullination and carbamylation, result in the
generation of two non-standard amino acids in polypeptides, citrulline and homocitrulline, respec-
tively, which are chemically highly related. Peptidylcitrulline is produced by the deimination of
peptidylarginine, which is catalyzed by peptidylarginine deiminases (PADs), a family of structurally
related enzymes that show distinct tissue-specific expression patterns (1). Peptidylhomocitrulline is
the product of the reaction of cyanate (OCN)- with peptidyllysine. The side chains of both citrulline
and homocitrulline are characterized by the presence of an ureido group (-NH-CO-NH2); the dif-
ference is the length of the side chains, which is one methylene longer in homocitrulline (Figure 1).
Citrullination has been reported to be associated with a variety of diseases, including cancer,
neurodegenerative diseases, and autoimmune diseases (1). Carbamylation has been implicated in
atherosclerosis, kidney disease, and inflammation (2). A special case is rheumatoid arthritis (RA), in
which a frequent humoral immune response to proteins containing (homo)citrulline was observed.
The resulting autoantibodies to citrullinated proteins (ACPA) are considered to represent the most
specific biomarker for RA and the presence of these autoantibodies in patient sera has been added
to the criteria for the classification of RA in 2010. The more recently identified anti-carbamylated
protein (anti-CarP) autoantibodies also show specificity for RA and, at least in part, appeared to
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FIGURE 1 | The central role of citrullination and carbamylation in the
pathology of RA. The exposure to certain environmental factors (e.g., smoking
or an infection with Porphyromonas gingivalis) leads to local protein modification
by citrullination and/or carbamylation. In conjunction with an inflammatory
process, this may elicit an immune response to citrullinated and/or
carbamylated proteins in genetically susceptible individuals. A secondary event
associated with inflammation in synovial joints results in citrullination and/or
carbamylation in these tissues, e.g., as a result of NETosis, which is followed by
activation of the ACPA/anti-CarP response and spreading of the autoantibody
response to multiple modified epitopes, generated by PAD activation and
release to the extracellular space. Certain immune complexes will boost the
inflammatory process, which ultimately will result in arthritis. The continuous
presence of activated PAD in the inflamed joints may also lead to the functional
inactivation of extracellular matrix proteins and chemokines, which further
contributes to tissue destruction. Also the autoantibodies produced may
contribute to the latter process by directly activating osteoclasts.
overlap with ACPA reactivities, although also anti-CarP-positive,
ACPA-negative patients have been described.
Citrullination has been reported to be involved in hair growth,
skin keratinization, myelin formation, the regulation of gene
expression, extracellular trap formation, and several other pro-
cesses [reviewed in Ref. (1)]. It is not yet known whether car-
bamylation has physiological functions. Conditions that enhance
cyanate levels, such as uremia, lead to the accumulation of car-
bamylated proteins.
There is increasing evidence for a pathophysiological role of
protein citrullination and carbamylation, and of the autoantibod-
ies to these proteins in RA. The elucidation of the corresponding
molecular mechanisms is complicated due to the heterogeneity of
citrullinated and carbamylated proteins and the heterogeneity of
the autoantibodies to these proteins. To better understand these
processes, high-throughput tools and techniques are required to
characterize the “citrullinome” and “carbamylome”, both in health
and disease, and to obtain more insight in the spectrum of ACPA
and anti-CarP specificities. In this article, I will briefly discuss
new technologies for the detection of such proteins, address the
substrate specificity of the PAD enzymes, and describe stud-
ies aimed at the identification of citrullinated and carbamylated
proteins in diseased tissues of RA. Furthermore, I will address
the questions how tolerance to citrullinated and carbamylated
antigens breaks and autoantibody production begins and I will
discuss the (potential) role of these forms of protein modification
in pathophysiological processes.
Methods to Detect Citrullinated and
Carbamylated Proteins
The ability to identify and quantify citrullinated and carbamylated
proteins is key to understanding the role of these PTMs in phys-
iological and pathophysiological processes. The specific detec-
tion of peptidyl(homo)citrulline in complex biological samples
is challenging due to the very small chemical difference between
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citrulline and arginine on the one hand and homocitrulline and
lysine on the other hand. Moreover, with many methods the dis-
crimination between citrullinated and homocitrullinated proteins
is hard or not possible. The most widely applied method for pep-
tidylcitrulline is the so-called anti-modified citrulline approach,
originally developed by Dr. Tatsuo Senshu in Japan (3). In this
method, the proteins are incubated with compounds that are
specifically reactive with the ureido side chain, resulting in an
adduct that can be detected with anti-modified citrulline anti-
bodies. Many results obtained with this elegant approach, how-
ever, have to be re-evaluated, because this method will detect
carbamylated proteins as efficiently as citrullinated proteins and
there is increasing evidence that carbamylation occurs under
(patho)physiological conditions (4).
Unfortunately, several attempts to elicit new anti-modified cit-
rulline antibodies in rabbits failed. To some extent, the lack of
these antibodies could be solved by using antibodies that target the
citrullinated isoforms of specific proteins, e.g., anti-citrullinated
fibrinogen and anti-citrullinated chemokine antibodies. For stud-
ies that are aimed at the global detection of citrullinated or car-
bamylated proteins such antibodies are obviously not suitable,
but recently monoclonal anti-modified citrulline antibodies have
been generated, which can be applied in the procedure originally
developed by Dr. Senshu.
Another method that was recently described to be applicable
for the detection of (homo)citrulline containing proteins is based
on the chemical reaction of the ureido group with phenylgly-
oxal under highly acidic conditions. Methods to detect citrulli-
nated/carbamylated proteins in complex samples based on this
compound, however, appeared to be hampered by relatively high
background reactivities (4).
Finally, the analysis of proteins by mass spectrometry provides
very attractive possibilities to identify and characterize citrulli-
nated and carbamylated proteins. For more information on the
applicability of these methods, I refer the reader to several recent
review articles (4, 5). Compared to other techniques, one of the
main advantages of mass spectrometry is that it discriminates
between citrullination (mass increase 0.98Da) and carbamylation
(mass increase 43.02Da) and that by tandem mass spectrometry
also the modification site can be mapped. We have used mass
spectrometric approaches to get more information on the sub-
strate specificity of PAD enzymes and to characterize citrullinated
proteins in synovial fluid samples of RA patients, which will be
addressed in the following paragraphs.
Specificity of Citrullination and
Carbamylation (PAD; MPO)
Since peptidylcitrulline is generated by an enzymaticmodification
and peptidylhomocitrulline results from a chemical modifica-
tion reaction, the specificity of citrullination will generally be
higher than that of carbamylation. Several studies have addressed
the substrate requirements for PAD enzymes. Although both
favored and disfavored amino acids at positions flanking the
deiminated arginine have been identified, the results demon-
strated that it is difficult to derive a consensus sequence for
citrullination sites. Nevertheless, for the four amino acids flanking
the hPAD4 citrullination site, two on each side, the proposed con-
sensus sequence is (M/K)–(D/S)–R–(G/D)–(H/W). The results
also demonstrated that the human PAD4 displays a more pro-
nounced substrate specificity than the human PAD2 (6).
Unlike citrullination, carbamylation is a chemicalmodification,
which ismainly induced by the presence of cyanate. The formation
of cyanate may result in a reaction with any accessible primary
amine, including that of the lysine side chain and the amine at
the N-terminus of polypeptides. Carbamylation can be stimulated
by myeloperoxidase (MPO), which is most abundantly expressed
in neutrophils, and which can convert thiocyanate coming from
cigarette smoke or dietary compounds into (iso)cyanate in the
presence of hydrogen peroxide. Also the spontaneous degradation
of urea, which is constantly and ubiquitously generated in the
body, results in the formation of cyanate (2). Although under nor-
mal physiological circumstances, cyanate levels will be too low to
induce substantial carbamylation, conditions like uremia, inflam-
mation, and the exposure to cigarette smoke enhance cyanate
levels.
Citrullinated Proteins in RA
In view of the putative pathophysiologic role of citrullinated
protein-specific immune complexes (see below) in RA, it is impor-
tant to obtain a comprehensive view of the citrullinated proteins
present in the inflamed joints of patients with RA. A systematic
analysis of citrullinated proteins present in the synovial fluid of
RA patients by mass spectrometry led to the identification of 53
polypeptides containing one or more citrulline residues, which
comprises 28% of all proteins identified (7). A comparison of the
data obtained with material from different patients indicates that
this is probably only aminority of the citrullinated proteins occur-
ring in the inflamed joints of RA patients, implying that many
proteins will be citrullinated in these tissues. Among the proteins
that were found to be citrullinated were fibrinogen, vimentin,
fibronectin, and histones, proteins that were reported to be mod-
ified in inflamed tissues in previous studies. When the nature and
frequency of amino acids flanking the citrulline were compared
with the substrate specificity data described above, this suggested
that citrullination in the RA synovium is exerted by a combina-
tion of PAD enzymes, e.g., PAD2 and PAD4. Indeed, both PAD2
and PAD4 have been reported to be expressed in the inflamed
synoviumofRApatients, in contrast to the other PAD isotypes (8).
Currently, hardly anything is known about the identity of car-
bamylated proteins that may play a role in autoimmunity. How-
ever, because in vivo carbamylation is mainly dependent on the
activity ofMPO (located in granules of neutrophils) and hydrogen
peroxide (generated by activated neutrophils), many proteins are
also expected to become carbamylated in the inflamed joints.
Extracellular Traps
During inflammation, e.g., caused by infections with bacteria,
yeast, or viruses, neutrophils initiate a programed cell death
termed NETosis. This process results in the release of unwound
chromatin from the cells, termed neutrophil extracellular traps
(NETs). Also other inflammatory cells have been demonstrated to
produce extracellular traps upon activation by pro-inflammatory
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stimuli. Most interestingly, PAD4 activity has been found to be
required for NETosis and citrullinated histones are incorporated
into NETs (9). It is likely that activated PAD4 is also released
from the neutrophils during NETosis and this may lead to the
citrullination of additional proteins in the extracellular space.
Also, deficiencies in neutrophil MPO result in impaired release of
NET chromatin. In addition to the association with citrullinated
histones, extracellular traps are decorated with anti-microbial
compounds originating fromneutrophil granules, includingMPO
(10). Thus, extracellular traps represent macromolecular assem-
blies, which are potentially associated with both citrullination
and carbamylation and therefore it is tempting to speculate
that they play a role in the initiation of the (homo)citrulline-
specific immune response in RA or in the progression of this
response. Indeed, autoantibodies to citrullinated histones have
been detected in RA patients, patients with systemic lupus ery-
thematosus (SLE) and patients with Felty’s syndrome (FS).
Citrullination and Carbamylation in
Pathophysiological Processes
The first autoimmune disease in which citrullination was sug-
gested to play a role was multiple sclerosis (MS). Myelin basic
protein (MBP) is one of the proteins that is citrullinated under
normal physiologic conditions, but in MS hypercitrullination
of this protein was observed, and the resulting MBP isoforms
differentially react with T-cells fromMS patients (11).
Several studies have demonstrated that the humoral immune
response to citrullinated (and carbamylated) proteins in RA is not
merely an epiphenomenon. A pathophysiologic role is supported
by the very early induction of ACPA and anti-CarP antibodies in
RA, often long before the disease becomes clinically manifested,
themore severe progression of the disease in seropositive patients,
the induction of arthritis in animal models upon immunization
with citrullinated antigens, and the exacerbation of arthritis by
ACPA in murine models of arthritis (12).
As a consequence of the very early generation of ACPA and
anti-CarP antibodies it is difficult to obtain information on
the factors triggering the immune response to these modified
proteins. Nevertheless, it is well known that genetic and envi-
ronmental factors play an important role (Figure 1). Smoking
(cigarette) has been demonstrated to be a prominent risk factor
and genome-wide analyses have identified multiple genes that are
associated with the development of RA (genome-wide associa-
tion studies have identified more than 100 risk loci). Another
environmental risk factor is the periodontal pathogen Porphy-
romonas gingivalis, which expresses an enzyme with peptidy-
larginine deiminase activity. It has been hypothesized that in
genetically susceptible individuals an inflammation in the lungs
or the oral cavity may lead to autoantigen citrullination that
triggers the generation of ACPA or anti-CarP antibodies (13,
14). Although this will not immediately lead to arthritis, a sec-
ondary event that is associated with joint inflammation may acti-
vate the (homo)citrulline-specific B-cells and subsequently the
immune response may spread to other citrullinated/carbamylated
epitopes generated in the inflamed joints. It is interesting to note
that smoking results in elevated thiocyanate levels in the lungs,
which can be converted by MPO into cyanate in the presence
of hydrogen peroxide. Therefore, in a subset of RA patients, the
ACPA/anti-CarP response may have been triggered by carbamy-
lated autoantigens in the lungs. Alternatively, in the case of a P.
gingivalis infection, autoantigen citrullination may be catalyzed
by either activated PAD from neutrophils or by the bacterial
PAD.
Several studies show that the recognition of citrullinated
autoantigens is not restricted to B cells. In the context of a proper
genetic background (HLA-DRB1 shared epitope), also T cells may
be activated by citrullinated epitopes and play a role in the etiology
of RA. RA patients recently were reported to have significantly
higher frequencies of peripheral citrulline-specific T cells than
healthy subjects (15).
The role of NET-associated citrullination and carbamylation in
these processes remains to be established. As already mentioned
above, prominent NET autoreactivity has been detected in the
sera from patients with RA, SLE, and FS. Autoantibodies to
citrullinated histones appeared to be produced in the majority of
FS patients and in a subset of RA and SLE patients (9). It is still an
open question whether these reactivities are due to ACPA and/or
anti-CarP antibodies that are cross reactive with citrullinated
epitopes of histones or whether these antibodies were elicited
by citrullinated histones. Additional evidence for a functional
relationship between NETosis and autoimmunity came from
experiments in which circulating (RA, SLE) and synovial fluid
(RA) neutrophils from autoimmune patients were shown to
display enhanced NETosis compared to neutrophils from healthy
controls and from osteoarthritis patients, respectively. Moreover,
RA sera and immunoglobulin fractions from RA patients which
high levels of ACPA and/or rheumatoid factor significantly
enhance NETosis (16). Finally, SLE sera were reported to have
a reduced capacity to degrade NETs. Taken together, these data
indicate that autoimmunity, at least in RA and SLE, is associated
with changes in NET formation and/or degradation, but the
involvement of NET-associated citrullinated and carbamylated
proteins is yet unknown.
Direct effects of citrullination in pathophysiological processes,
especially in RA, may also originate from the citrullination of
extracellular matrix proteins, like fibronectin and collagen II,
which affects integrin-mediated cell adhesion (17). Citrullination
has also been reported to affect the activity of chemokines, which
may dysregulate the network in which these immunomodulators
function, leading to uncontrolled inflammation (18).
In view of the limited specificity of carbamylation, it is likely
that the function of multiple proteins is affected by this type
of modification under conditions associated with elevated levels
of cyanate. However, autoimmunity-related pathophysiological
processes directly mediated by the carbamylation of proteins
involved, have not been identified yet.
Concluding Remarks
Citrullination and carbamylation have been demonstrated to
represent PTM that are important for the generation of an
immune response in several autoimmune diseases, particularly
RA. Increasing evidence points to a role of the modified proteins
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and the immune response mounted against these proteins in
pathophysiological processes in these diseases. However, it is
important to note that citrullination and, to a lesser extent, car-
bamylation have normal physiological functions and the differ-
entiation between physiological and pathological citrullination
and carbamylation remains to be defined, both qualitatively and
quantitatively.
Also the pathologic stimuli of citrullination and carbamyla-
tion are still largely unknown, although there are strong indi-
cations that in the case of RA modification of proteins in the
lung and/or the gums induced by environmental factors may
initiate an immune response. Moreover, a role for extracellular
traps and the release of enzymes and molecules from the cells
during extracellular trap formation has been suggested. In the
inflamed joints of RA patients, many proteins are citrullinated
and this modification can have consequences for the biochemical
function of these proteins, as well as for the immune response and
immune complex formation. It remains an open question which
citrullinated epitopes are most relevant for pathophysiological
processes.
The disease-specificity of the ACPA and anti-CarP immune
responses, as well as the evidence for the involvement of the cor-
responding protein modifications and these antibodies in patho-
physiological processes, strongly suggest that modulation of cit-
rullination and/or carbamylation might be a potential therapeutic
approach to treat patientswithRAandother autoimmune diseases
associated with these modifications. Therefore, future studies
should be aimed at defining themost relevant (homo)citrullinated
epitopes, determination of the enzyme isotype(s), and envi-
ronmental factors that play the most important role, and the
generation of molecules that can interfere with the molecular
interactions and conversions involved in a highly specific manner.
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